Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Heather Raymon"'
Autor:
Paul Rogers, Bitna Yang, Hyojin Kim, Yusun Kim, Sunglim Cho, Bret Morin, Amanda Conerty, Lavakumar Karyampudi, Lisa Guerrettaz, Peter Flynn, Bokyung Min, Heather Raymon
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Gina Chu, Kun-Yu Teng, Lisa Guerrettaz, Rodrigo Fernades Da Silva, Salvatore Rotondo, Claudia Palomino La Torre, Amanda Conerty, Peter Flynn, Anita Seto, Heather Raymon, Srinivas Somanchi
Publikováno v:
Blood. 140:7419-7420
Autor:
Rashmi Khanal, Jennifer N. Saultz, Umar Farooq, Sunita Nathan, Amitkumar Mehta, Ayad Hamdan, Lawrence E. Morris, Houston Holmes, Lauren C. Pinter-Brown, John K.C. Lim, Amanda Conerty, Heather Raymon, Peter Flynn, Anita G. Seto, Joseph J. Maly
Publikováno v:
Blood. 140:12742-12743
Autor:
Amer M. Zeidan, Daniel J. DeAngelo, Jeanne Palmer, Christopher S. Seet, Martin S. Tallman, Xin Wei, Heather Raymon, Priya Sriraman, Stephan Kopytek, Jan Philipp Bewersdorf, Michael R. Burgess, Kristen Hege, Wendy Stock
Publikováno v:
Ann Hematol
Annals of hematology, vol 101, iss 3
Annals of hematology, vol 101, iss 3
CC-90002 is an anti-CD47 antibody that inhibits CD47-SIRPα interaction and enables macrophage-mediated killing of tumor cells in hematological cancer cell lines. In this first clinical, phase 1, dose-escalation and -expansion study (CC-90002-AML-001
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91f68a10cbb5afd2ba7d9f1d2b4832d5
https://europepmc.org/articles/PMC9414073/
https://europepmc.org/articles/PMC9414073/
Autor:
Johanna C. Bendell, John Nemunaitis, George R. Blumenschein, Heather Raymon, Amit Mahipal, Barbara Eichhorst, Christophe Massard, David Smith, Pamela N. Munster, Hans A. de Haan, Timothy F. Cloughesy, Dana E. Rathkopf, Monica M. Mita, Cristina Cruz, Luis Paz-Ares, Tom Mikkelsen, Shaoyi Li, Kristen Hege, Manuel Hidalgo, Ellen Filvaroff
Publikováno v:
Cancer Management and Research. 11:10463-10476
Author(s): Munster, Pamela; Mita, Monica; Mahipal, Amit; Nemunaitis, John; Massard, Christophe; Mikkelsen, Tom; Cruz, Cristina; Paz-Ares, Luis; Hidalgo, Manuel; Rathkopf, Dana; Blumenschein, George; Smith, David C; Eichhorst, Barbara; Cloughesy, Tim;
Autor:
Shuichan Xu, Tam Tran, Dan Zhu, Tao Shi, David Mikolon, Jim Leisten, Philip Chamberlain, Laurie LeBrun, Sogole Bahmanyar, Ning Jiang, Jingjing Zhao, Mehnaz Malek, Ellen Filvaroff, Heather Raymon, Robert Hubbard, John Boylan
Publikováno v:
Cancer Research. 82:1180-1180
CC-91516 (also called CC0776314), a selective and potent inhibitor of ERK1/2 and NLK, was discovered via a phenotypic screen of a kinase-focused library for compounds that synergize with mTOR kinase inhibitor CC-223 to induce apoptosis in combination
Autor:
Shuichan Xu, Ning Jiang, Rama K. Narla, Jennifer Riggs, Tao Shi, Sophie X. Peng, Yuhong Ning, Heather Raymon, Dan Zhu, Gordafaried Deyanat-Yazdi, David Mikolon, John F. Boylan, Leo Barnes, Tam Tran
Publikováno v:
Molecular Cancer Therapeutics. 17:1727-1738
Historically, phenotypic-based drug discovery has yielded a high percentage of novel drugs while uncovering new tumor biology. CC-671 was discovered using a phenotypic screen for compounds that preferentially induced apoptosis in triple-negative brea
Autor:
Yu-Kyeong Hwang, Sang-Min Paik, Hyeong Jin Nam, Srinivas S. Somanchi, Han Sol Kim, Jason Litten, Eugene Helsel, Amanda Medcalf, Eun-Sol Lee, H. Lim, Yusun Kim, Bokyung Min, Lisa Guerrettaz, Eun Ji Choi, Peter Flynn, Eun Ji Kim, Jeong Min Kim, Heather Raymon, Bitna Yang, Seungryel Han
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A138-A138
BackgroundHuman Epidermal Growth Factor Receptor 2 (HER2), is a receptor tyrosine kinase that is highly expressed on the surface of many solid tumors. While many patients derive meaningful benefit from the approved HER2-directed therapies, most will
Autor:
Heather Raymon, Bonny Gaffney, Deborah Mortensen, Wong Lilly L, Sabita Sankar, Tam Tran, Lisa M. Sapinoso, Shuichan Xu, Toshiya Tsuji
Publikováno v:
Oncotarget
// Toshiya Tsuji 1 , Lisa M. Sapinoso 1 , Tam Tran 1 , Bonny Gaffney 1 , Lilly Wong 1 , Sabita Sankar 1 , Heather K. Raymon 2 , Deborah S. Mortensen 3 and Shuichan Xu 1 1 Oncology Research, Celgene Corporation, San Diego, CA 92121, USA 2 Pharmacology
Autor:
Brian E. Cathers, Thomas O. Daniel, Emily Rychak, Rama K. Narla, Heather Raymon, Ling Lu, Rajesh Chopra, Yuhong Ning, Anita Gandhi, Antonia Lopez-Girona, Chad C. Bjorklund, Karen Miller, Tao Shi, Jim Leisten, Derek Mendy, Anjan Thakurta, Robert Z. Orlowski
Publikováno v:
British Journal of Haematology. 172:889-901
Pomalidomide is an IMiD(®) immunomodulatory agent, which has shown clinically significant benefits in relapsed and/or refractory multiple myeloma (rrMM) patients when combined with dexamethasone, regardless of refractory status to lenalidomide or bo